A new business deal may help ensure that future generations of people at risk for diabetes can enjoy good health and avoid the medical complications and high life insurance rates that tend to come with a diagnosis.
According to an announcement from Linkoping University in Sweden, a recent deal with a U.S. pharmaceutical company may see a vaccine for type 1 diabetes on the market as early as 2012.
The announcement noted that under the deal, Ortho-McNeil-Janssen Pharmaceuticals, which is owned by Johnson & Johnson, will invest $45 million in Diamyd Medical to complete the third phase of medical trials currently underway in Europe and the U.S. for the vaccine.
If the vaccine is successful, it has the potential to alter the healthcare landscape as it currently stands. After all, diabetes rates have skyrocketed in the U.S. in conjunction with the dramatic rise in obesity rates.
As a pre-existing condition, diabetes is often a trigger for higher life insurance premiums. This is because it tends to shorten the life expectancy of those with the condition due to the toll it takes on various parts of the body.